(Amendment No. 7)*
Alexandra A. Toohey
Baker Bros. Advisors LP
(Name, address and telephone number of
person authorized to receive notices and communications)
*The remainder of this cover page shall
be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page
shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise
subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.
CUSIP No. 50015M109
|
|
Page 2 of 11 Pages
|
1.
|
NAMES OF REPORTING PERSONS
Baker Bros. Advisors LP
|
2.
|
CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) ¨
(b) ¨
|
3.
|
SEC USE ONLY
|
4.
|
SOURCE OF FUNDS*
OO
|
5.
|
CHECK
BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) o
|
6.
|
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING
PERSON WITH
|
7.
|
SOLE VOTING POWER: 14,717,292 (1)
|
8.
|
SHARED VOTING POWER: 0
|
9.
|
SOLE DISPOSITIVE POWER: 14,717,292 (1)
|
10.
|
SHARED DISPOSITIVE POWER: 0
|
11.
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:
14,717,292 (1)
|
12.
|
CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* ¨
|
13.
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
28.5% (1)(2)
|
14.
|
TYPE OF REPORTING PERSON*
IA, PN
|
|
|
|
|
|
|
(1) Includes 35,988 shares of common stock (“Common
Stock”) of Kodiak Sciences Inc. (the “Issuer”) underlying 35,988 non-qualified options exercisable for Common Stock
(“Stock Options”).
(2) Based on 51,474,570 shares of Common Stock outstanding
as of September 1, 2021, as reported in the Issuer’s Schedule 14A filed with the Securities and Exchange Commission (“SEC”)
on September 13, 2021, plus 149,983 shares of Common Stock that were issued upon exercise of warrants as described in Item 5 herein.
CUSIP No. 50015M109
|
|
Page 3 of 11 Pages
|
1.
|
NAMES OF REPORTING PERSONS
Baker Bros. Advisors (GP) LLC
|
2.
|
CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) ¨
(b) ¨
|
3.
|
SEC USE ONLY
|
4.
|
SOURCE OF FUNDS*
OO
|
5.
|
CHECK
BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) o
|
6.
|
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING
PERSON WITH
|
7.
|
SOLE VOTING POWER: 14,717,292 (1)
|
8.
|
SHARED VOTING POWER: 0
|
9.
|
SOLE DISPOSITIVE POWER: 14,717,292 (1)
|
10.
|
SHARED DISPOSITIVE POWER: 0
|
11.
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:
14,717,292 (1)
|
12.
|
CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* ¨
|
13.
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
28.5% (1)(2)
|
14.
|
TYPE OF REPORTING PERSON*
HC, OO
|
|
|
|
|
(1) Includes 35,988 shares of Common Stock underlying 35,988
Stock Options.
(2) Based on 51,474,570 shares of Common Stock outstanding
as of September 1, 2021 as reported in the Issuer’s Schedule 14A filed with the SEC on September 13, 2021, plus 149,983 shares of
Common Stock that were issued upon exercise of warrants as described in Item 5 herein.
CUSIP No. 50015M109
|
|
Page 4 of 11 Pages
|
1.
|
NAMES OF REPORTING PERSONS
Felix J. Baker
|
2.
|
CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) ¨
(b) ¨
|
3.
|
SEC USE ONLY
|
4.
|
SOURCE OF FUNDS*
OO
|
5.
|
CHECK
BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) o
|
6.
|
CITIZENSHIP OR PLACE
OF ORGANIZATION
United States
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING
PERSON WITH
|
7.
|
SOLE VOTING POWER:
14,717,292 (1)
|
8.
|
SHARED VOTING POWER: 0
|
9.
|
SOLE DISPOSITIVE POWER: 14,717,292 (1)
|
10.
|
SHARED DISPOSITIVE POWER: 0
|
11.
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON: 14,717,292 (1)
|
12.
|
CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* ¨
|
13.
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
28.5% (1)(2)
|
14.
|
TYPE OF REPORTING PERSON*
IN, HC
|
|
|
|
|
(1) Includes 35,988 shares of Common Stock underlying 35,988
Stock Options.
(2) Based on 51,474,570 shares of Common Stock outstanding
as of September 1, 2021 as reported in the Issuer’s Schedule 14A filed with the SEC on September 13, 2021, plus 149,983 shares of
Common Stock that were issued upon exercise of warrants as described in Item 5 herein.
CUSIP No. 50015M109
|
|
Page 5 of 11 Pages
|
1.
|
NAMES OF REPORTING PERSONS
Julian C. Baker
|
2.
|
CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) ¨
(b) ¨
|
3.
|
SEC USE ONLY
|
4.
|
SOURCE OF FUNDS*
OO
|
5.
|
CHECK
BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) ¨
|
6.
|
CITIZENSHIP OR PLACE
OF ORGANIZATION
United States
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING
PERSON WITH
|
7.
|
SOLE VOTING POWER:
14,717,292 (1)
|
8.
|
SHARED VOTING POWER: 0
|
9.
|
SOLE DISPOSITIVE POWER: 14,717,292 (1)
|
10.
|
SHARED DISPOSITIVE POWER: 0
|
11.
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON: 14,717,292 (1)
|
12.
|
CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* ¨
|
13.
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
28.5% (1)(2)
|
14.
|
TYPE OF REPORTING PERSON*
IN, HC
|
|
|
|
|
|
|
(1) Includes 35,988 shares of Common Stock underlying 35,988
Stock Options.
(2) Based on 51,474,570 shares of Common Stock outstanding
as of September 1, 2021 as reported in the Issuer’s Schedule 14A filed with the SEC on September 13, 2021, plus 149,983 shares of
Common Stock that were issued upon exercise of warrants as described in Item 5 herein.
Amendment No. 7 to Schedule 13D
This Amendment No. 7 to Schedule 13D amends and supplements
the previously filed Schedules 13D filed by Baker Bros. Advisors LP (the “Adviser”), Baker Bros. Advisors (GP) LLC
(the “Adviser GP”), Julian C. Baker and Felix J. Baker (collectively the “Reporting Persons”). Except as
supplemented herein, such statements, as heretofore amended and supplemented, remain in full force and effect.
The Adviser GP is the sole general partner of the Adviser. Pursuant
to the management agreements, as amended, among the Adviser, Baker Brothers Life Sciences, L.P. (“Life Sciences”) and
667, L.P. (“667”, and together with Life Sciences, the “Funds”), and their respective general partners,
the Funds’ respective general partners relinquished to the Adviser all discretion and authority with respect to the investment
and voting power over securities held by the Funds, and thus the Adviser has complete and unlimited discretion and authority with
respect to the Funds’ investments and voting power over investments.
All capitalized terms contained herein but not otherwise defined
shall have the meanings ascribed to such terms in the Schedule 13D, as amended. Information given in response to each item shall
be deemed incorporated by reference in all other items, as applicable.
ITEM 3.
|
Source and Amount of Funds or Other Consideration
|
Item 3 of this Schedule 13D is supplemented and
superseded, as the case may be, as follows:
The disclosure in Item 5 are incorporated herein, by reference.
ITEM 5.
|
Interest in Securities of the Issuer
|
Item 5 of this Schedule 13D is hereby amended and restated in its entirety
as follows:
(a) and (b) Items 7 through 11 and 13 of each of the cover pages of
this Amendment No. 7 are incorporated herein by reference.
Set forth below is the aggregate number of shares of Common Stock (“Common
Stock”) of Kodiak Sciences Inc. (the “Issuer”) directly held by each of the Funds, which may be deemed to be indirectly
beneficially owned by the Reporting Persons.
Holder
|
|
Common Stock
|
|
667, L.P.
|
|
|
1,154,578
|
|
Baker Brothers Life Sciences, L.P.
|
|
|
13,526,726
|
|
Total
|
|
|
14,681,304
|
|
On September
29, 2021, 667 and Life Sciences exercised warrants to acquire 11,184 shares and 138,815 shares, respectively, of Common Stock at
an exercise price of $0.01 per share, with such warrants having an expiration date of August 11, 2022 (the “2022
Warrants”). 667 and Life Sciences exercised the 2022 Warrants on a cashless basis resulting in the Issuer withholding 2 and 14,
respectively, of the 2022 Warrant shares in lieu of paying the exercise price in cash and issuing to 667 and Life Sciences the remaining
11,182 and 138,801 shares of Common Stock, respectively.
The Adviser GP, Felix J. Baker and Julian C. Baker as managing members
of the Adviser GP, and the Adviser may be deemed to be beneficial owners of securities of the Issuer directly held by the Funds.
Felix J. Baker, a managing member of the Adviser GP, currently serves
on the Issuer’s Board of Directors (the “Board”). He is Chair of the Compensation Committee and serves on the Nominating/Governance
Committee. Felix J. Baker, as compensation for his service on the Board, receives non-qualified stock options to purchase shares of Common
Stock of the Issuer (“Stock Options”). Felix J. Baker holds 24,747 vested Stock Options that have an exercise price of $10.13
per share and expire on June 2, 2029, 4,135 vested Stock Options that have an exercise price of $62.50 per share and expire on June 7,
2030, 7,106 vested Stock Options that have an exercise price of $54.12 per share and expire on June 29, 2030, and 7,368 Stock Options
which were granted on June 30, 2021, have an exercise price of $93.00 per share, expire on June 29, 2031, and which will vest on the earlier
of June 30, 2022 or one day prior to the next annual meeting of the Issuer’s stockholders. The policy of the Funds and the Adviser
does not permit managing members of the Adviser GP to receive compensation for serving as directors of the Issuer, and the Funds are instead
entitled to the pecuniary interest in any compensation received for their service.
(c) The following transactions in the Issuer’s Common Stock were
effected by Life Sciences during the sixty days preceding the filing of this statement using its working capital. All purchase transactions
were effected in the open market directly with a broker-dealer. Except as disclosed herein, none of the Reporting Persons nor their affiliates
has effected any other transactions in securities of the Issuer during the past 60 days.
Name
|
|
Date
|
|
Number of Shares
|
|
|
Transaction
|
|
Price/Share
|
|
|
Footnote
|
|
Baker Brothers Life Sciences, L.P.
|
|
8/11/2021
|
|
|
3,723
|
|
|
Purchase
|
|
|
84.3903
|
|
|
|
1
|
|
Baker Brothers Life Sciences, L.P.
|
|
8/11/2021
|
|
|
600
|
|
|
Purchase
|
|
|
85.7229
|
|
|
|
2
|
|
Baker Brothers Life Sciences, L.P.
|
|
8/11/2021
|
|
|
44,700
|
|
|
Purchase
|
|
|
86.0734
|
|
|
|
3
|
|
Baker Brothers Life Sciences, L.P.
|
|
8/11/2021
|
|
|
4,500
|
|
|
Purchase
|
|
|
87.9978
|
|
|
|
4
|
|
Baker Brothers Life Sciences, L.P.
|
|
8/12/2021
|
|
|
300
|
|
|
Purchase
|
|
|
85.5800
|
|
|
|
|
|
Baker Brothers Life Sciences, L.P.
|
|
8/12/2021
|
|
|
4,600
|
|
|
Purchase
|
|
|
86.4447
|
|
|
|
5
|
|
Baker Brothers Life Sciences, L.P.
|
|
8/12/2021
|
|
|
6,086
|
|
|
Purchase
|
|
|
88.0109
|
|
|
|
6
|
|
Baker Brothers Life Sciences, L.P.
|
|
8/13/2021
|
|
|
21,595
|
|
|
Purchase
|
|
|
88.5870
|
|
|
|
7
|
|
Baker Brothers Life Sciences, L.P.
|
|
8/13/2021
|
|
|
16,269
|
|
|
Purchase
|
|
|
88.7588
|
|
|
|
8
|
|
Baker Brothers Life Sciences, L.P.
|
|
8/13/2021
|
|
|
400
|
|
|
Purchase
|
|
|
88.8150
|
|
|
|
|
|
Baker Brothers Life Sciences, L.P.
|
|
8/17/2021
|
|
|
400
|
|
|
Purchase
|
|
|
84.8025
|
|
|
|
9
|
|
Baker Brothers Life Sciences, L.P.
|
|
8/17/2021
|
|
|
7,764
|
|
|
Purchase
|
|
|
85.9522
|
|
|
|
10
|
|
Baker Brothers Life Sciences, L.P.
|
|
8/18/2021
|
|
|
12,898
|
|
|
Purchase
|
|
|
87.7890
|
|
|
|
11
|
|
Baker Brothers Life Sciences, L.P.
|
|
8/18/2021
|
|
|
8,186
|
|
|
Purchase
|
|
|
87.9134
|
|
|
|
12
|
|
Baker Brothers Life Sciences, L.P.
|
|
8/18/2021
|
|
|
1,100
|
|
|
Purchase
|
|
|
88.1650
|
|
|
|
|
|
Baker Brothers Life Sciences, L.P.
|
|
8/18/2021
|
|
|
400
|
|
|
Purchase
|
|
|
89.6563
|
|
|
|
13
|
|
Baker Brothers Life Sciences, L.P.
|
|
8/19/2021
|
|
|
2,968
|
|
|
Purchase
|
|
|
86.9385
|
|
|
|
14
|
|
Baker Brothers Life Sciences, L.P.
|
|
8/19/2021
|
|
|
4,649
|
|
|
Purchase
|
|
|
87.0710
|
|
|
|
15
|
|
Baker Brothers Life Sciences, L.P.
|
|
8/19/2021
|
|
|
2,396
|
|
|
Purchase
|
|
|
87.4821
|
|
|
|
16
|
|
Baker Brothers Life Sciences, L.P.
|
|
8/19/2021
|
|
|
73,635
|
|
|
Purchase
|
|
|
87.6141
|
|
|
|
17
|
|
Baker Brothers Life Sciences, L.P.
|
|
9/7/2021
|
|
|
5,300
|
|
|
Purchase
|
|
|
92.8829
|
|
|
|
18
|
|
Baker Brothers Life Sciences, L.P.
|
|
9/7/2021
|
|
|
52,201
|
|
|
Purchase
|
|
|
93.3497
|
|
|
|
19
|
|
Baker Brothers Life Sciences, L.P.
|
|
9/15/2021
|
|
|
30,285
|
|
|
Purchase
|
|
|
94.3842
|
|
|
|
20
|
|
Baker Brothers Life Sciences, L.P.
|
|
9/15/2021
|
|
|
400
|
|
|
Purchase
|
|
|
94.4775
|
|
|
|
21
|
|
Baker Brothers Life Sciences, L.P.
|
|
9/16/2021
|
|
|
1,153
|
|
|
Purchase
|
|
|
94.5918
|
|
|
|
22
|
|
Baker Brothers Life Sciences, L.P.
|
|
9/30/2021
|
|
|
86,932
|
|
|
Purchase
|
|
|
95.8286
|
|
|
|
23
|
|
(1) The reported price is a weighted average price. These shares were
traded in multiple transactions at a prices ranging from $84.23 to $84.88. The Reporting Persons undertake to provide the staff of the
Securities and Exchange Commission (the “Staff”), upon request, full information regarding the number of shares traded at
each separate price within the ranges set forth in this footnote.
(2) The reported price is a weighted average price. These shares were
traded in multiple transactions at prices ranging from $84.91 to $85.89. The Reporting Persons undertake to provide the Staff, upon request,
full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.
(3) The reported price is a weighted average price. These shares were
traded in multiple transactions at prices ranging from $85.52 to $86.45. The Reporting Persons undertake to provide the Staff, upon request,
full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.
(4) The reported price is a weighted average price. These shares were
traded in multiple transactions at prices ranging from $87.99 to $88.00. The Reporting Persons undertake to provide the Staff, upon request,
full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.
(5) The reported price is a weighted average price. These shares were
traded in multiple transactions at prices ranging from $86.04 to $87.00. The Reporting Persons undertake to provide the Staff, upon request,
full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.
(6) The reported price is a weighted average price. These shares were
traded in multiple transactions at prices ranging from $87.32 to $88.25. The Reporting Persons undertake to provide the Staff, upon request,
full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.
(7) The reported price is a weighted average price. These shares were
traded in multiple transactions at prices ranging from $88.30 to $88.90. The Reporting Persons undertake to provide the Staff, upon request,
full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.
(8) The reported price is a weighted average price. These shares were
traded in multiple transactions at prices ranging from $88.41 to $89.00. The Reporting Persons undertake to provide the Staff, upon request,
full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.
(9) The reported price is a weighted average price. These shares were
traded in multiple transactions at prices ranging from $84.69 to $84.92. The Reporting Persons undertake to provide the Staff, upon request,
full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.
(10) The reported price is a weighted average price. These shares were
traded in multiple transactions at prices ranging from $85.86 to $86.00. The Reporting Persons undertake to provide the Staff, upon request,
full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.
(11) The reported price is a weighted average price. These shares were
traded in multiple transactions at prices ranging from $87.52 to $88.37. The Reporting Persons undertake to provide the Staff, upon request,
full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.
(12) The reported price is a weighted average price. These shares were
traded in multiple transactions at prices ranging from $87.75 to $88.50. The Reporting Persons undertake to provide the Staff, upon request,
full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.
(13) The reported price is a weighted average price. These shares were
traded in multiple transactions at prices ranging from $89.61 to $89.73. The Reporting Persons undertake to provide the Staff, upon request,
full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.
(14) The reported price is a weighted average price. These shares were
traded in multiple transactions at prices ranging from $86.70 to $87.10. The Reporting Persons undertake to provide the Staff, upon request,
full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.
(15) The reported price is a weighted average price. These shares were
traded in multiple transactions at prices ranging from $86.59 to $87.45. The Reporting Persons undertake to provide the Staff, upon request,
full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.
(16) The reported price is a weighted average price. These shares were
traded in multiple transactions at prices ranging from $87.20 to $87.67. The Reporting Persons undertake to provide the Staff, upon request,
full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.
(17) The reported price is a weighted average price. These shares were
traded in multiple transactions at prices ranging from $87.11 to $88.10. The Reporting Persons undertake to provide the Staff, upon request,
full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.
(18) The reported price is a weighted average price. These shares were
traded in multiple transactions at prices ranging from $92.86 to $92.90. The Reporting Persons undertake to provide the Staff, upon request,
full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.
(19) The reported price is a weighted average price. These shares were
traded in multiple transactions at prices ranging from $93.00 to $93.92. The Reporting Persons undertake to provide the Staff, upon request,
full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.
(20) The reported price is a weighted average price. These shares were
traded in multiple transactions at prices ranging from $93.81 to $94.64. The Reporting Persons undertake to provide the Staff, upon request,
full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.
(21) The reported price is a weighted average price. These shares were
traded in multiple transactions at prices ranging from $94.46 to $94.50. The Reporting Persons undertake to provide the Staff, upon request,
full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.
(22) The reported price is a weighted average price. These shares were
traded in multiple transactions at prices ranging from $94.45 to $94.73. The Reporting Persons undertake to provide the Staff, upon request,
full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.
(23) The reported price is a weighted average price. These shares were
traded in multiple transactions at prices ranging from $95.15 to $95.98. The Reporting Persons undertake to provide the Staff, upon request,
full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.
(d) Certain securities of the Issuer are held directly by 667, a limited
partnership the sole general partner of which is Baker Biotech Capital, L.P., a limited partnership the sole general partner of which
is Baker Biotech Capital (GP), LLC. Julian C. Baker and Felix J. Baker are the managing members of Baker Biotech Capital (GP), LLC.
Certain securities of the Issuer are held directly by Life Sciences,
a limited partnership the sole general partner of which is Baker Brothers Life Sciences Capital, L.P., a limited partnership the sole
general partner of which is Baker Brothers Life Sciences Capital (GP), LLC. Julian C. Baker and Felix J. Baker are the managing members
of Baker Brothers Life Sciences Capital (GP), LLC.
(e) Not applicable.
|
Item 6.
|
Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the
Issuer
|
Item 6 of this Schedule 13D is supplemented and
superseded, as the case may be, as follows:
The disclosure in Item 5 regarding the exercise of the 2022 Warrants
is incorporated herein by reference.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this statement is true, complete and correct.
October 1, 2021
|
BAKER BROS. ADVISORS LP
By: Baker Bros. Advisors (GP) LLC, its general partner
|
|
|
|
|
By:
|
/s/ Scott L. Lessing
|
|
|
Name: Scott L. Lessing
Title: President
|
|
BAKER BROS. ADVISORS (GP) LLC
|
|
|
|
|
By:
|
/s/ Scott L. Lessing
|
|
|
Name: Scott L. Lessing
Title: President
|
|
/s/ Julian C. Baker
|
|
Julian C. Baker
|
|
/s/ Felix J. Baker
|
|
Felix J. Baker
|